We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ACTU

Price
7.47
Stock movement down
-0.01 (-0.13%)
Company name
Actuate Therapeutics, Inc. Common stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
159.01M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-12.80%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-09-12

iO Charts is a Seeking Alpha partner

DIVIDENDS

ACTU does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

FINANCIALS

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open7.60
Daily high7.67
Daily low7.46
Daily Volume17K
All-time high11.90
1y analyst estimate26.75
Beta-
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ACTUS&P500
Current price drop from All-time high-35.59%-1.46%
Highest price drop-52.44%-56.47%
Date of highest drop21 Jul 20259 Mar 2009
Avg drop from high-21.50%-10.99%
Avg time to new high37 days12 days
Max time to new high88 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ACTU (Actuate Therapeutics, Inc. Common stock) company logo
Marketcap
159.01M
Marketcap category
Small-cap
Description
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Employees
10
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...